

1 Kathleen S. O’Neill (PA Bar No. 82785)
 2 Joseph Chandra Mazumdar (WI Bar No. 1030967)
 3 Brian E. Hanna (VA Bar No. 80439)
 4 Robert A. Lepore (AZ Bar No. 028137)
 5 Tai Milder (CABN 267070)
 6 United States Department of Justice, Antitrust Division
 7 450 Fifth Street, NW, Suite 8000
 8 Washington, DC 20530
 9 Telephone: (202) 307-2931
 10 Fax: (202) 307-2874
 11 Email: kathleen.oneill@usdoj.gov

12 Brian J. Stretch (CABN 163973)
 13 United States Attorney
 14 [Additional counsel listed on signature page]

15 Attorneys for Plaintiff United States of America

16 UNITED STATES DISTRICT COURT
 17 FOR THE NORTHERN DISTRICT OF CALIFORNIA
 18 SAN FRANCISCO DIVISION

19 UNITED STATES OF AMERICA,
 20 Plaintiff,
 21 v.
 22 VA PARTNERS I, LLC
 23 VALUEACT CAPITAL MASTER FUND, L.P.
 24 VALUEACT CO-INVEST INTERNATIONAL, L.P.,
 25 Defendants.

Civil Action No.:

26 **COMPLAINT**

27 The United States of America, acting under the direction of the Attorney General of the
 28 United States, brings this civil action to obtain civil penalties and equitable relief against the
 Defendants (collectively, “ValueAct”) for failing to comply with the premerger notification and
 waiting period requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976
 (“HSR Act”), and alleges as follows:

I. INTRODUCTION

1
2 1. The Hart-Scott-Rodino Act, 15 U.S.C. §18a, is an essential part of modern
3 antitrust enforcement. It requires purchasers of voting securities in excess of a certain value to
4 notify the Department of Justice and the Federal Trade Commission and to observe a waiting
5 period before consummating the transaction. These obligations extend to acquisitions of
6 minority interests. One limited exemption to these obligations applies if the purchaser's holdings
7 constitute less than ten percent of the stock of the company and the acquisition is "solely for the
8 purpose of investment" – that is, the purchaser has no intention of participating in the company's
9 business decisions.

10 2. ValueAct promotes itself as having a strategy of "active, constructive
11 involvement" in the management of the companies in which it invests. This case concerns recent
12 acquisitions by two ValueAct investment funds of over \$2.5 billion of voting securities of
13 Halliburton Company and Baker Hughes Incorporated. Halliburton and Baker Hughes are head-
14 to-head competitors and two of the largest providers of oilfield products and services in the
15 world. On November 17, 2014, Halliburton and Baker Hughes announced their intent to merge.
16 Their proposed merger is the subject of an ongoing antitrust review in the United States and
17 several other countries.

18 3. ValueAct began acquiring significant holdings of the two companies on the heels
19 of the Halliburton/Baker Hughes merger announcement. From the beginning, ValueAct
20 anticipated influencing the business decisions of the companies as the merger process unfolded.
21 ValueAct sent memoranda to its investors outlining this strategy and explaining that purchasing a
22 stake in each of these firms would allow it to "be a strong advocate for the deal to close," which
23 would in turn "[i]ncrease probability of deal happening." If the deal encountered "regulatory
24 issues," ValueAct "would be well positioned as an owner of both companies to help develop the
25 new terms." ValueAct executives also discussed internally a back-up plan to "sell at least some
26 of Baker's pieces" if the deal were blocked or abandoned.

27 4. ValueAct's purchases of Halliburton and Baker Hughes shares did not qualify for
28 the narrow exemption from the requirements of the HSR Act for acquisitions made solely for the

1 purpose of investment. ValueAct planned from the outset to take steps to influence the business
2 decisions of both companies, and met frequently with executives of both companies to execute
3 those plans.

4 5. These HSR Act violations allowed ValueAct to become one of the largest
5 shareholders of both Halliburton and Baker Hughes, without providing the government its
6 statutory right to notice and prior review of the stock purchases. ValueAct established these
7 positions as Halliburton and Baker Hughes were being investigated for agreeing to a merger that
8 threatens to substantially lessen competition in numerous markets. ValueAct intended to use its
9 position as a major shareholder of these companies to obtain access to management, to learn
10 information about the merger and the companies' strategies in private conversations with senior
11 executives, to influence those executives to improve the chances that the merger would be
12 completed, and to influence other business decisions whether or not the merger went forward.

13 6. The Court should assess a civil penalty of at least \$19 million to address
14 ValueAct's violations of the HSR Act, and should restrain ValueAct from further violations.

15 **II. JURISDICTION AND VENUE**

16 7. This Complaint is filed and these proceedings are instituted under Section 7A of
17 the Clayton Act, 15 U.S.C. § 18a, added by Title II of the HSR Act, to recover civil penalties and
18 equitable relief for violations of that section.

19 8. This Court has jurisdiction over the Defendants and over the subject matter of this
20 action pursuant to Section 7A(g) of the Clayton Act, 15 U.S.C. § 18a(g), and pursuant to
21 28 U.S.C. §§ 1331, 1337(a), 1345 and 1355. Each of the Defendants is engaged in commerce, or
22 in activities affecting commerce, within the meaning of Section 1 of the Clayton Act, 15 U.S.C.
23 § 12, and Section 7A(a)(1) of the Clayton Act, 15 U.S.C. § 18a(a)(1).

24 9. Venue is properly based in this District under Section 12 of the Clayton Act, 15
25 U.S.C. § 22, and under 28 U.S.C. § 1391(b)(2), (c)(2). Each of the Defendants transacts or has
26 transacted business in this district and has its principal place of business here.

27 ///

28 ///

ValueAct Capital Submission in Response to Second Request issued on 1/27/2016 and 2/10/2016 - Business Confidential - Confidential Treatment Requested

ABILITY TO INFLUENCE: OUR "ACTIVISM" SCORECARD

Total Core Investments	79
Public Board Seats	41
Proxy Contest*	1
CEO/CFO Changes	33
Major Divestitures	14
Recaps/Big Share Repurchases	26
Operating Consultant Engagements	14
Acquisition/Investment Strategy	11
Company Sales	19
Compensation Changes	9

*Settled before vote

22

14. In presentations, ValueAct has explained that it likes "disciplined oligopolies" and looks to invest in businesses in "[o]ligopolistic markets, high barriers-to-entry."

15. ValueAct funds have previously violated the HSR Act by acquiring voting securities without making the required notifications. In 2003, ValueAct Capital Partners, L.P. filed corrective notifications for three prior acquisitions of voting securities. ValueAct outlined steps it would take to ensure future compliance with the HSR Act. No enforcement action was taken at that time. Master Fund then failed to make required filings with respect to three acquisitions that it made in 2005. ValueAct agreed to pay a \$1.1 million civil penalty to settle an HSR Act enforcement action based on these violations.

V. BACKGROUND

A. **The Hart-Scott-Rodino Antitrust Improvements Act**

16. The HSR Act requires parties to file a notification with the Federal Trade Commission and the Department of Justice and to observe a waiting period before consummating acquisitions of voting securities or assets that exceed certain value thresholds.

1 These requirements give the antitrust enforcement agencies prior notice of, and information
2 about, proposed transactions. The waiting period also provides the antitrust enforcement
3 agencies with an opportunity to investigate and to seek an injunction to prevent the
4 consummation of anticompetitive transactions.

5 17. The HSR Act contains certain limited exemptions to the notification and waiting
6 period requirements. The acquirer of voting securities has the burden of showing eligibility for
7 an exemption. One such exemption applies narrowly to acquisitions made “solely for the
8 purpose of investment” if the voting securities held do not exceed ten percent of the outstanding
9 voting securities of the issuer. 15 U.S.C. § 18a(c)(9). The regulations implementing the Act
10 explain that, to qualify for this exemption, the acquiring party must have “no intention of
11 participating in the formulation, determination, or direction of the basic business decisions of the
12 issuer.” 16 C.F.R. § 801.1(i)(1).

13 **B. ValueAct’s Initial Investment Decision and Strategy**

14 18. After Halliburton and Baker Hughes announced their intent to merge on
15 November 17, 2014, ValueAct began purchasing stock in each company through its Master Fund
16 and Co-Invest Fund. ValueAct continued to make purchases in both companies for several
17 months, eventually acquiring over \$2.5 billion in securities of the two companies combined.

18 19. As ValueAct was acquiring stock in these two companies in December 2014 and
19 early January 2015, its executives were developing strategies to use ValueAct’s ownership
20 position to influence management of each firm as necessary to increase the probability of the
21 deal being completed. ValueAct’s Master Fund crossed the applicable HSR Act reporting
22 thresholds for Baker Hughes and Halliburton on December 1 and December 5, 2014,
23 respectively, and Master Fund continued to build up its position as its executives discussed
24 strategy. These discussions culminated in the drafting of memoranda that ValueAct sent to its
25 investors on January 16, 2015. These memoranda – one about Baker Hughes and one about
26 Halliburton – explained ValueAct’s decision to acquire stakes in these competitors through its
27 Master Fund, and offered investors the opportunity to increase their stakes in these firms through
28 additional share purchases by ValueAct’s Co-Invest Fund.

1 20. These memoranda and other contemporaneous documents show that ValueAct's
2 most senior executives planned from the outset to play an active role at Halliburton and Baker
3 Hughes. The lead ValueAct partner responsible for the Baker Hughes investment internally
4 circulated a draft of an investor memorandum explaining that "our activist approach limits our
5 downside in the unlikely case that the merger does not close." The draft further noted that if the
6 merger were not completed, ValueAct "would likely seek to take a more active role in
7 overseeing the company." ValueAct's CEO then requested an insertion into the memorandum
8 highlighting that ValueAct's "[a]ctive role" is an additional reason to invest in both companies.

9 21. Although the memoranda ultimately shared with investors watered down the
10 words used to describe ValueAct's activist strategy, they still emphasized that purchasing a stake
11 in Halliburton and Baker Hughes would "increase probability of deal happening" and would
12 allow ValueAct to be "a strong advocate for the deal to close." ValueAct identified this as one
13 of three "key considerations" supporting its investment decision. A contemporaneous email
14 among ValueAct partners remarked that if Halliburton's shareholders threatened to vote against
15 the deal, ValueAct's "position in HAL should be meaningful enough to have a substantial role in
16 those conversations."

17 22. ValueAct also intended to help restructure the merger if it hit roadblocks. On
18 December 16, 2014, ValueAct's CEO emailed his partners: "if we own both we can drive new
19 terms to get the deal done if weird [expletive] is happening." ValueAct also expressed this view
20 in its memos to investors: "In the event of further fundamental dislocation or regulatory issues,
21 it is possible the deal would need to be restructured and we believe ValueAct Capital would be
22 well positioned as an owner of both companies to help develop the new terms."

23 23. In a December 2014 internal email, a ValueAct partner observed that "[i]f the deal
24 failed, the back-up plan would seem to be to sell at least some of Baker's pieces, and we think
25 that we could get up to 12x EBITDA for just 2 of BHI's businesses – artificial lift and
26 chemicals." ValueAct's memoranda to investors noted, "Recent transactions in each of those
27 industries [specialty chemicals and artificial lift] suggest that these businesses are worth north of
28 10 times EBITDA." Moreover, the Baker Hughes memorandum explained that there are

1 “numerous levers for the company to pull to drive margin expansion,” and identified Baker
2 Hughes’s pressure pumping business as a good candidate for margin improvement.

3 24. Regardless of how the merger process unfolded, ValueAct intended to influence
4 the business decisions of both companies. For example, on December 5, 2014, the day Master
5 Fund’s holdings in Halliburton crossed the HSR Act threshold, a ValueAct partner wrote an
6 email to ValueAct’s CEO about Halliburton: “Wonder if it would be possible to get the VRX
7 [Valeant Pharmaceuticals] comp plan in from outside the board room?” The CEO responded
8 “Yes. Good idea.” (ValueAct had recently convinced management to change the executive
9 compensation plan at another of its investments, Valeant Pharmaceuticals.)

10 25. ValueAct also intended to play a role in Halliburton’s efforts to integrate the two
11 firms. ValueAct told its investors that its stake in Halliburton “helps to further enhance our
12 relationship with management and the board of directors as they work to complete the merger
13 and integrate the business into Halliburton’s existing operations.”

14 **C. ValueAct’s Efforts to Influence the Management of Both Companies**

15 26. Consistent with its investment strategy of “active, constructive involvement,”
16 ValueAct established a direct line to senior management at both Halliburton and Baker Hughes
17 and met with them frequently from the time it started acquiring stock. From December 2014
18 through January 2016, ValueAct met in person or had teleconferences more than fifteen times
19 with senior management of Halliburton or Baker Hughes, including meeting multiple times with
20 the CEOs of both companies. ValueAct partners also exchanged a number of emails with
21 management at both firms about the merger and the companies’ respective operations.

22 27. ValueAct reached out to Baker Hughes immediately after it began purchasing
23 shares. On December 1, 2014, the day Master Fund’s holdings crossed the HSR Act threshold
24 for Baker Hughes, a ValueAct partner told a Baker Hughes executive that ValueAct was positive
25 on the merger but also liked “that 20% of [Baker Hughes’s] revenue comes from non-capital
26 intensive business lines which could command a big multiple if sold.” A few days later,
27 ValueAct’s CEO met in person with the CFO of Baker Hughes. According to Baker Hughes’s
28 notes of the meeting, ValueAct’s CEO “highlighted that it was critical that BHI continued

1 focused [*sic*] on many of these improvement opportunities despite the acquisition. He
2 specifically emphasized with graphs the largest gap/opportunities he saw.” With respect to the
3 gap in Baker Hughes’s North American margins, ValueAct’s CEO stated, “Looking to learn with
4 BHI on how to close that GAP [*sic*].” ValueAct’s CEO also discussed other areas “that he
5 thought BHI should continue to focus on as there was a lot of improvement opportunity.”
6 According to the notes, the meeting ended with ValueAct’s CEO “stating that they would remain
7 in contact and sharing that they plan to be large shareholders of BHI.”

8 28. On January 16, 2015, ValueAct filed a Beneficial Ownership Report
9 (Schedule 13D) with the Securities and Exchange Commission publicly disclosing its substantial
10 stake in Baker Hughes and reporting that it might discuss “competitive and strategic matters”
11 with Baker Hughes management, and might “propos[e] changes in [Baker Hughes’s]
12 operations.” Before submitting the Schedule 13D, ValueAct’s CEO notified Halliburton’s CEO
13 of the impending filing on Baker Hughes, explaining that the filing “gives us the flexibility to
14 engage with the company [Baker Hughes] on all issues.” Later the same day, ValueAct’s CEO
15 emailed Halliburton’s CEO a copy of its investment memoranda for both Halliburton and Baker
16 Hughes.

17 29. By February, after ValueAct had completed its outreach to investors seeking
18 capital for additional share purchases, ValueAct began acquiring stock in Halliburton and Baker
19 Hughes through Co-Invest Fund. On March 10, 2015, Co-Invest Fund’s holdings in Halliburton
20 crossed the applicable HSR Act reporting threshold.

21 30. Also in early March, ValueAct contacted Halliburton to offer assistance in
22 advance of the shareholder vote on the merger. ValueAct offered Halliburton “to speak with any
23 of [Halliburton’s] top shareholders about [ValueAct’s] view of the merger prior to the vote.”
24 Halliburton responded that it would let ValueAct know if ValueAct’s help became necessary.

25 31. In May 2015, ValueAct further engaged with Halliburton on the company’s plans
26 for post-merger integration. On May 13, ValueAct met with Halliburton’s CEO to discuss
27 actions that Halliburton could take in an attempt to achieve its target merger synergies. On
28 May 27, a ValueAct partner called Halliburton’s Chief Integration Officer to recommend a firm

1 for real estate integration services. In a subsequent email exchange, another ValueAct partner
2 emphasized the need to engage on these issues at the executive level, and stated that
3 Halliburton's plan was "a traditional approach likely to leave value on the table." Instead, the
4 partner identified alternative ways the real estate firm could work with Halliburton to help
5 achieve the synergy goals.

6 32. ValueAct also followed through on its idea for changing Halliburton's executive
7 compensation plan. On July 14, 2015, ValueAct contacted Halliburton's CEO to schedule a
8 meeting to discuss executive compensation. At the meeting, which ultimately occurred in
9 September, ValueAct delivered a thirty-five-page presentation detailing ValueAct's preferred
10 approach, commenting on Halliburton's current plan, and proposing specific changes.

11 **D. Consistent with Its Initial Plans, ValueAct Worked to Restructure the**
12 **Merger or to Sell Parts of Baker Hughes**

13 33. ValueAct carefully monitored the status of the antitrust review process and
14 intended to intervene with the management of each firm as necessary to increase the probability
15 of the deal being completed. ValueAct met with Baker Hughes's CEO in May 2015 and
16 according to ValueAct's notes of that meeting, Baker Hughes's CEO "seemed pretty worried
17 about anti-trust, and implied odds deal goes through 70% or lower in his mind." ValueAct then
18 continued to push management of both companies to preserve the deal or, if these efforts failed,
19 to sell off pieces of Baker Hughes.

20 34. On August 31, 2015, ValueAct met with Baker Hughes's CEO "to plant the seed
21 to seek alternative options with other buyers if the deal falls through." In its initial investment
22 analysis, the ValueAct partners had discussed selling individual Baker Hughes businesses as a
23 back-up plan if the merger failed. ValueAct presented an updated analysis to argue this case to
24 Baker Hughes. ValueAct also proposed restructuring the deal with Halliburton, suggesting that
25 Baker Hughes should sell its pressure pumping, artificial lift, and specialty chemical businesses
26 to Halliburton at a premium in lieu of receiving the merger termination fee.

27 35. According to ValueAct notes from the meeting, Baker Hughes's CEO was "very
28 committed to running BHI stand-alone if the deal fails and did not seem to entertain the idea of

1 shopping the business piecemeal to other buyers.” The notes explain that ValueAct agreed that
2 the Baker Hughes CEO’s plan to “focus on technology-based product lines, and grow the
3 business organically in these areas seems like the right areas to focus for the stand-alone
4 company.” But this plan was not what the ValueAct executives hoped for: “the problem is that
5 this story seems like a 4-5 year period with the stock not generating a great return over that
6 period.” According to Baker Hughes’s notes of the meeting, the ValueAct executives registered
7 disappointment with Baker Hughes’s CEO, and informed him that Halliburton and Baker
8 Hughes were “the only investment ValueAct had where they did not have board seats.”

9 36. On September 18, 2015, ValueAct pitched its restructuring plan to Halliburton’s
10 CEO, advocating that Halliburton pursue selective acquisitions of Baker Hughes’s production
11 chemicals and artificial lift businesses. According to Halliburton’s notes of the call, ValueAct
12 suggested that Halliburton should offer a substantial sum to acquire these businesses and settle
13 the \$3.5 billion merger break-up fee at the same time.

14 37. During this conversation with the CEO of Halliburton, ValueAct shared Baker
15 Hughes’s plans if the merger could not close. According to Halliburton’s notes of the call,
16 ValueAct stated that if the merger could not be consummated, Baker Hughes’s CEO intended to
17 “run the company like he did before.” Halliburton’s CEO then asked whether Baker Hughes’s
18 CEO was “listening to VA.” A ValueAct partner replied that Baker Hughes’s CEO “realize [*sic*]
19 can go to his board directly.” ValueAct also asked Halliburton’s CEO if there was “anything we
20 [ValueAct] can do to be helpful,” and explicitly offered to “apply pressure to BHI CEO
21 regarding unhappiness if he continues to run co. if deal does not go through.” In short, ValueAct
22 offered to use its position as a shareholder to pressure Baker Hughes’s management to change its
23 business strategy in ways that could affect Baker Hughes’s competitive future.

24 38. ValueAct and Halliburton’s willingness to discuss the competitive future of Baker
25 Hughes in the absence of a merger is further confirmed by notes contained in ValueAct’s files.
26 These notes list “3 options that Lazard [presumably Halliburton’s CEO, David Lesar] discussed”
27 with respect to Baker Hughes. One of those options was “Cripple a competitor.”
28

1 39. On November 5, 2015, ValueAct made a detailed fifty-five page presentation to
2 Baker Hughes's CEO proposing operational and strategic changes to the company. The same
3 day, ValueAct lobbied Halliburton's senior management to pursue alternative ways to get the
4 deal done.

5 **VI. VIOLATIONS ALLEGED**

6 40. Plaintiff alleges and incorporates paragraphs 1 through 39 as if set forth fully
7 herein.

8 41. The HSR Act provides that any person, or any officer, director, or partner thereof,
9 who fails to comply with any provision of the HSR Act is liable to the United States for a civil
10 penalty for each day during which such person is in violation. Master Fund and Co-Invest Fund
11 are each considered a separate person under the Act and are each obligated to comply with its
12 requirements.

13 **A. Count 1: Master Fund's Acquisition of Halliburton**

14 42. The HSR Act and applicable implementing regulations required that Master Fund
15 file a notification and report form with the antitrust enforcement agencies and observe a waiting
16 period before acquiring any voting securities in Halliburton that would result in Master Fund
17 holding an aggregate total amount of voting securities in excess of the \$50 million threshold, as
18 adjusted (\$75.9 million in December 2015, and \$76.3 million beginning in February 2016).

19 43. On or about December 4, 2014, Master Fund began purchasing Halliburton voting
20 securities. On or about December 5, 2014, Master Fund's aggregate value of Halliburton voting
21 securities exceeded the \$75.9 million threshold. Master Fund continued to purchase Halliburton
22 voting securities until June 30, 2015, by which time Master Fund's aggregate value of
23 Halliburton voting securities exceeded \$1.4 billion.

24 44. Master Fund failed to file the required notification or to observe the required
25 waiting period.

26 45. On or about January 27, 2016, Master Fund had sold a sufficient quantity of
27 voting securities of Halliburton such that its holdings were no longer in excess of \$76.3 million.
28

1 46. Master Fund was in violation of the requirements of the HSR Act related to its
2 purchase of Halliburton voting securities each day beginning December 5, 2014, and ending on
3 or about January 27, 2016.

4 **B. Count 2: Co-Invest Fund's Acquisition of Halliburton**

5 47. The HSR Act and applicable implementing regulations required that Co-Invest
6 Fund file a notification and report form with the antitrust enforcement agencies and observe a
7 waiting period before acquiring any voting securities in Halliburton that would result in Co-
8 Invest Fund holding an aggregate total amount of voting securities in excess of the \$50 million
9 threshold, as adjusted (\$76.3 million beginning in February 2016).

10 48. On or about February 24, 2015, Co-Invest Fund began purchasing Halliburton
11 voting securities. On or about March 10, 2015, Co-Invest Fund's aggregate value of Halliburton
12 voting securities exceeded the \$76.3 million threshold. Co-Invest Fund continued to purchase
13 Halliburton voting securities until March 12, 2015, by which time Co-Invest Fund's aggregate
14 value of Halliburton voting securities exceeded \$138 million.

15 49. Co-Invest Fund failed to file the required notification or observe the required
16 waiting period.

17 50. On or about January 22, 2016, Co-Invest Fund had sold a sufficient quantity of
18 voting securities of Halliburton such that its holdings were no longer in excess of \$76.3 million.

19 51. Co-Invest Fund was in violation of the requirements of the HSR Act related to its
20 purchase of Halliburton voting securities each day beginning March 10, 2015, and ending on or
21 about January 22, 2016.

22 **C. Count 3: Master Fund's Acquisition of Baker Hughes**

23 52. The HSR Act and applicable implementing regulations required that Master Fund
24 file a notification and report form with the antitrust enforcement agencies and observe a waiting
25 period before acquiring any voting securities in Baker Hughes that would result in Master Fund
26 holding an aggregate total amount of voting securities in excess of the \$50 million threshold, as
27 adjusted (\$75.9 million in December 2015, and \$76.3 million beginning in February 2016).

1 53. On or about November 28, 2014, Master Fund began purchasing Baker Hughes
2 voting securities. On or about December 1, 2014, Master Fund's aggregate value of Baker
3 Hughes voting securities exceeded the \$75.9 million threshold. Master Fund continued to
4 purchase Baker Hughes voting securities until January 15, 2015, by which time Master Fund's
5 aggregate value of Baker Hughes voting securities exceeded \$1.2 billion.

6 54. Master Fund failed to file the required notification or to observe the required
7 waiting period.

8 55. Master Fund was in violation of the requirements of the HSR Act related to its
9 purchase of Baker Hughes voting securities each day beginning on December 1, 2014, and
10 remains in violation of the HSR Act to the present.

11 **VII. REQUEST FOR RELIEF**

12 Wherefore, Plaintiff requests:

13 (a) That the Court adjudge and decree that Defendant Master Fund's acquisitions of
14 voting securities of Halliburton, without having filed a notification and report form and
15 observing a waiting period, violated the HSR Act;

16 (b) That the Court adjudge and decree that Defendant Co-Invest Fund's acquisitions
17 of voting securities of Halliburton, without having filed a notification and report form and
18 observing a waiting period, violated the HSR Act;

19 (c) That the Court adjudge and decree that Defendant Master Fund's acquisitions of
20 voting securities of Baker Hughes, without having filed a notification and report form and
21 observing a waiting period, violated the HSR Act;

22 (d) That the Court order Defendants to pay to the United States an appropriate civil
23 penalty as provided by the HSR Act, 15 U.S.C. § 18a(g)(1), the Debt Collection Improvement
24 Act of 1996, Pub. L. 104-134, § 31001(s) (amending the Federal Civil Penalties Inflation
25 Adjustment Act of 1990, 28 U.S.C. § 2461 note), and Federal Trade Commission Rule 1.98,
26 16 C.F.R. § 1.98, 74 Fed. Reg. 858 (Jan. 9, 2009);

27 (e) That the Court enjoin Defendants from any future violations of the HSR Act;
28

1 (f) That the Court order such other and further relief as the Court may deem just and
2 proper; and,

3 (g) That the Court award the Plaintiff its costs of this suit.


4 Dated:

5 Respectfully submitted,


6 FOR THE PLAINTIFF UNITED STATES
7 OF AMERICA:
8

9 

10 WILLIAM J. BAER
11 Assistant Attorney General
12



13 JOSEPH CHANDRA MAZUMDAR
14 BRIAN E. HANNA
15 TAI MILDER
16 Trial Attorneys

17 

18 DAVID I. GELFAND
19 Deputy Assistant Attorney General

20 United States Department of Justice
21 Antitrust Division
22 450 Fifth Street, NW
23 Suite 8000
24 Washington, DC 20530
25 Telephone: (202) 307-2931
26 kathleen.oneill@usdoj.gov

27 

28 PATRICIA A. BRINK (CABN 144499)
29 Director of Civil Enforcement

30 

31 KATHLEEN S. O'NEILL
32 Chief, Transportation, Energy, and
33 Agriculture Section

34 

35 BRIAN J. STRETCH (CABN 163973)
36 United States Attorney
37 By JONATHAN U. LEE (CABN 148792)
38 Acting Chief, Civil Division
39 Assistant U.S. Attorney
40 Office of the United States Attorney
41 Northern District of California
42 450 Golden Gate Avenue
43 San Francisco, CA 94102
44 Telephone: (415) 436-7200
45 E-mail: jonathan.lee@usdoj.gov

46 

47 ROBERT A. LEPORE
48 Assistant Chief, Transportation, Energy, and
49 Agriculture Section

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS
United States of America

(b) County of Residence of First Listed Plaintiff _____
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)
Kathleen S. O'Neill (Attorney of Record), U.S. Department of Justice
Antitrust Division, 450 5th Street NW, Washington, D.C. 20530
TEL: (202) 307-2931
See Attachment A, "Plaintiff's Attorneys"

DEFENDANTS
VA Partners I, LLC
ValueAct Capital Master Fund, L.P.
ValueAct Co-Invest International, L.P.

County of Residence of First Listed Defendant San Francisco
(IN U.S. PLAINTIFF CASES ONLY)
NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)
See Attachment B, "Defendants' Attorneys"

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)
 1 U.S. Government Plaintiff
 2 U.S. Government Defendant
 3 Federal Question (U.S. Government Not a Party)
 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)
(For Diversity Cases Only)
Citizen of This State PTF 1 DEF 1
Citizen of Another State PTF 2 DEF 2
Citizen or Subject of a Foreign Country PTF 3 DEF 3
Incorporated or Principal Place of Business In This State PTF 4 DEF 4
Incorporated and Principal Place of Business In Another State PTF 5 DEF 5
Foreign Nation PTF 6 DEF 6

IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excludes Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise	PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury - Medical Malpractice	<input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 690 Other LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Management Relations <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 751 Family and Medical Leave Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Employee Retirement Income Security Act IMMIGRATION <input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 465 Other Immigration Actions	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609	<input type="checkbox"/> 375 False Claims Act <input type="checkbox"/> 400 State Reapportionment <input checked="" type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 896 Arbitration <input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision <input type="checkbox"/> 950 Constitutionality of State Statutes

V. ORIGIN (Place an "X" in One Box Only)
 1 Original Proceeding 2 Removed from State Court 3 Remanded from Appellate Court 4 Reinstated or Reopened 5 Transferred from Another District (specify) 6 Multidistrict Litigation

VI. CAUSE OF ACTION
Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
15 U.S.C. § 18a
Brief description of cause:
Failure to comply with the notification and waiting period requirements of the Hart-Scott-Rodino Antitrust Improvement Act of 1976

VII. REQUESTED IN COMPLAINT: CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$ _____ CHECK YES only if demanded in complaint: JURY DEMAND: Yes No

VIII. RELATED CASE(S) IF ANY (See instructions): JUDGE _____ DOCKET NUMBER _____

IX. DIVISIONAL ASSIGNMENT (Civil L.R. 3-2) (Place an "X" in One Box Only) (X) SAN FRANCISCO/OAKLAND () SAN JOSE () EUREKA

DATE 4/4/2016 SIGNATURE OF ATTORNEY OF RECORD [Signature]

United States of America v. ValueAct Capital Management, LP, et al.
Attachment A to Civil Cover Sheet
Plaintiff's Attorneys

Kathleen S. O'Neill*

Robert A. Lepore

Joseph Chandra Mazumdar

Brian E. Hanna

United States Department of Justice

Antitrust Division

Transportation, Energy and Agriculture

Section

450 Fifth Street NW, Suite 8000

Washington, D.C. 20530

Telephone: (202) 307-6349

Facsimile: (202) 307-2784

kathleen.oneill@usdoj.gov

robert.lepore@usdoj.gov

chan.mazumdar@usdoj.gov

brian.hanna2@usdoj.gov

Tai Milder

United States Department of Justice

Antitrust Division

San Francisco Field Office

450 Golden Gate Avenue

Box 36046, Room 10-0101

San Francisco, CA 94102-3478

Telephone: (415) 934-5338

Facsimile: (415) 934-5399

tai.milder@usdoj.gov

Jonathan U. Lee

Acting Chief, Civil Division

Office of the United States Attorney

450 Golden Gate Avenue

San Francisco, CA 94102

Telephone: (415) 436-7200

Facsimile: (415) 436-6748

jonathan.lee@usdoj.gov

*Attorney of Record

United States of America v. ValueAct Capital Management, LP, et al.
Attachment B to Civil Cover Sheet
Defendants' Attorneys

Bilal K. Sayyed

Kirkland & Ellis LLP
655 Fifteenth Street, N.W.
Washington, D.C. 20005
Telephone: (202) 879-5192
Facsimile: (202) 879-5200
bilal.sayyed@kirkland.com

Raymond A. Jacobson, Jr.

McDermott Will & Emery LLP
The McDermott Building
500 North Capital Street, N.W.
Washington, D.C. 20001
Telephone: (202) 756-8028
Facsimile: (202) 756-8087
rayjacobsen@mwe.com